Back to Stocks

LABT

Lakewood-Amedex Biotherapeutics Inc.
6 filings tracked
healthcarebiotechnologyMICRO (<$300M)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Lakewood-Amedex Biotherapeutics (LABT) has reached a pivotal structural turning point, transitioning from a capital-constrained entity to a Nasdaq-listed clinical-stage company.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the optics of a Nasdaq debut, the financial reality for Lakewood-Amedex is precarious. The company entered the quarter with a collapse in liquidity, with cash and equivalents plummeting to just $11.7 thousand by March 31, 2026.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every LABT filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The 10-Q filing paints a picture of a high-risk, high-reward biotech play that has successfully navigated a complex capital restructuring to achieve public market visibility. The immediate impact of the filing is the removal of immediate insolvency risk through the Series C raise and the conversion of debt to equity. However, the company remains a pre-revenue entity with a substantial accumulated deficit of $54.3 million and a heavy reliance on future equity markets to fund its clinical roadmap. The overarching narrative for investors is a trade-off between the ability to execute the Nu-3 clinical program and the risk of severe equity erosion. While the Nasdaq listing provides liquidity and a platform for growth, the structural vulnerabilities—specifically the variable conversion terms of the new preferred stock and the admitted internal control failures—suggest that the company's financial footing is far from stable. The success of the upcoming Phase 2a trial is now the primary catalyst that will determine if LABT can attract the further capital necessary to avoid a dilution spiral.

Selected Quarter

Core Takeaway

The company has cleared its debt via equity conversion and secured short-term funding, but remains highly dilutive and cash-poor.

Investor Lens

The trade-off between the potential of a breakthrough antimicrobial and the high probability of further equity dilution.

Watch Next

The commencement and initial data readouts from the Phase 2a safety and dose-response study for Nu-3.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.20Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 22

Raised $6.8 million net via Series C Preferred Stock to fund operations through 2026.

capital raise
70%
bullishMay 22

Converted $1.5 million in notes and $10.6 million in dividends into common stock.

debt restructure
60%
bearishMay 22

Net loss widened to $923k due to increased G&A and listing-related professional fees.

margin compression
50%
neutralMay 22

Successfully completed listing on the Nasdaq Capital Market.

regulatory action
40%
bullishMay 22

Raised $6.8 million net via Series C Preferred Stock to fund operations through 2026.

capital raise
70%
bullishMay 22

Converted $1.5 million in notes and $10.6 million in dividends into common stock.

debt restructure
60%
bearishMay 22

Net loss widened to $923k due to increased G&A and listing-related professional fees.

margin compression
50%
neutralMay 22

Successfully completed listing on the Nasdaq Capital Market.

regulatory action
40%
bullishMay 22

Raised $6.8 million net via Series C Preferred Stock to fund operations through 2026.

capital raise
70%
bullishMay 22

Converted $1.5 million in notes and $10.6 million in dividends into common stock.

debt restructure
60%
bearishMay 22

Net loss widened to $923k due to increased G&A and listing-related professional fees.

margin compression
50%
neutralMay 22

Successfully completed listing on the Nasdaq Capital Market.

regulatory action
40%
bullishMay 22

Raised $6.8 million net via Series C Preferred Stock to fund operations through 2026.

capital raise
70%
bullishMay 22

Converted $1.5 million in notes and $10.6 million in dividends into common stock.

debt restructure
60%
bearishMay 22

Net loss widened to $923k due to increased G&A and listing-related professional fees.

margin compression
50%
neutralMay 22

Successfully completed listing on the Nasdaq Capital Market.

regulatory action
40%
bullishMay 22

Raised $6.8 million net via Series C Preferred Stock to fund operations through 2026.

capital raise
70%
bullishMay 22

Converted $1.5 million in notes and $10.6 million in dividends into common stock.

debt restructure
60%
bearishMay 22

Net loss widened to $923k due to increased G&A and listing-related professional fees.

margin compression
50%
neutralMay 22

Successfully completed listing on the Nasdaq Capital Market.

regulatory action
40%
bullishMay 22

Raised $6.8 million net via Series C Preferred Stock to fund operations through 2026.

capital raise
70%
bullishMay 22

Converted $1.5 million in notes and $10.6 million in dividends into common stock.

debt restructure
60%
bearishMay 22

Net loss widened to $923k due to increased G&A and listing-related professional fees.

margin compression
50%
neutralMay 22

Successfully completed listing on the Nasdaq Capital Market.

regulatory action
40%

Filing History

10-QMay 22, 2026
Expand Sequence

The 10-Q filing paints a picture of a high-risk, high-reward biotech play that has successfully navigated a complex capital restructuring to achieve public market visibility. The immediate impact of the filing is the removal of immediate insolvency risk through the Series C raise and the conversion of debt to equity. However, the company remains a pre-revenue entity with a substantial accumulated deficit of $54.3 million and a heavy reliance on future equity markets to fund its clinical roadmap. The overarching narrative for investors is a trade-off between the ability to execute the Nu-3 clinical program and the risk of severe equity erosion. While the Nasdaq listing provides liquidity and a platform for growth, the structural vulnerabilities—specifically the variable conversion terms of the new preferred stock and the admitted internal control failures—suggest that the company's financial footing is far from stable. The success of the upcoming Phase 2a trial is now the primary catalyst that will determine if LABT can attract the further capital necessary to avoid a dilution spiral.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.